Company news

Quince Therapeutics, Inc. (NASDAQ:QNCX) news

Quince Therapeutics, Inc. news releases on 6ix. Latest, Sep 17, 2026: Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape…

Quince Therapeutics, Inc. (NASDAQ:QNCX) news

Press releases & updates

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Quince Therapeutics to Participate in September 2026 Investor Conferences

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Quince Therapeutics to Participate at Investor Events in December 2025

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Launches Scientific Advisory Board

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity

Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital

Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023

Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals